Enovis (ENOV) Stock: Buy, Sell, or Hold?
ENOV - Enovis Corporation
$20.81
0.12 (0.58%)
▲
5d:
+12.06%
30d:
+13.16%
90d:
-20.15%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 05, 2026
13d
Get Alerted When ENOV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ENOV shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ENOV shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$23.26
Based on 0.9% avg growth
INTRINSIC VALUE TODAY
$14.44
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 6.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ENOV is currently trading at $20.81, which is considered extended relative to its 30-day fair value range of $17.80 to $18.96. The stock's valuation (Forward PE: 5.9) is in line with its historical norms (6.3). Remarkably, the market is currently pricing in an annual earnings decline of 2.1% over the next few years. This pessimistic expectation contrasts with the company's recent 153.1% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ENOV is in a downtrend. Immediate support is located at $16.70, while resistance sits at $21.49.
Market Sentiment: ENOV scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $36.08 (+73.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ENOV is in a downtrend. Immediate support is located at $16.70, while resistance sits at $21.49.
Market Sentiment: ENOV scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $36.08 (+73.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$17.80 -
$18.96
Company Quality Score
36/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
23.8%
All Signals
- BEARISH: Price extended above range (+9.8% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 73.4% below Wall St target ($36.08)
- WARNING: Composite score 36/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$17.80 -
$18.96
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$16.70
Resistance Level
$21.49
Current Trend
Downtrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
5.87
Wall Street Target
$36.08
(+73.4%)
Revenue Growth (YoY)
3.2%
Earnings Growth (YoY)
153.1%
Profit Margin
-48.0%
Valuation Discount vs History
-2.1% cheaper
PE vs Historical
5.9 vs 6.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.1%
(market-implied from PE analysis)
1-Year Target
$20.37
(-2%)
2-Year Target
$19.95
(-4%)
3-Year Target
$19.53
(-6%)
3-Yr Target (if PE normalizes)
(PE: 6→6)
$20.95
(+1%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: -2.3%)
$65.60
(+215%)
Base:
(SPY PE: 5.9, Growth: -2.3%)
$19.40
(-7%)
Bear:
(PE: 5.0, Growth: -2.3%)
$16.49
(-21%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 5.9 to 6.3
Stabilization Target:
$22.32
(+7.3%)
PE Expansion Potential:
+7.3%
Share & Embed Analysis
Last updated: October 21, 2026 7:08 PM ET
Data refreshes hourly during market hours. Next update: 8:08 PM
Data refreshes hourly during market hours. Next update: 8:08 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ENOV showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
31 analysts |
$59 | 50 HOLD |
|
SYK
Stryker Corporation |
STRONG BUY
29 analysts |
$363 | 37 SELL |
|
MDT
Medtronic PLC |
BUY
29 analysts |
$105 | 43 HOLD |
|
AXGN
Axogen Inc |
STRONG BUY
12 analysts |
$54 | 75 BUY |
|
TNDM
Tandem Diabetes Care Inc |
BUY
25 analysts |
$28 | 54 HOLD |
